JP7898267B2 - 小胞体ストレス抑制剤、神経変性疾患予防改善剤および認知症の予防・進行防止・改善剤、並びに食品 - Google Patents

小胞体ストレス抑制剤、神経変性疾患予防改善剤および認知症の予防・進行防止・改善剤、並びに食品

Info

Publication number
JP7898267B2
JP7898267B2 JP2021171332A JP2021171332A JP7898267B2 JP 7898267 B2 JP7898267 B2 JP 7898267B2 JP 2021171332 A JP2021171332 A JP 2021171332A JP 2021171332 A JP2021171332 A JP 2021171332A JP 7898267 B2 JP7898267 B2 JP 7898267B2
Authority
JP
Japan
Prior art keywords
endoplasmic reticulum
triglyceride
prevention
cells
foods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021171332A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023061448A (ja
JP2023061448A5 (cg-RX-API-DMAC10.html
Inventor
誠 坪井
泰子 阪田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Refine Holdings Co Ltd
Original Assignee
Refine Holdings Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Refine Holdings Co Ltd filed Critical Refine Holdings Co Ltd
Priority to JP2021171332A priority Critical patent/JP7898267B2/ja
Priority to US18/702,472 priority patent/US20240415797A1/en
Priority to PCT/JP2022/038842 priority patent/WO2023068285A1/ja
Publication of JP2023061448A publication Critical patent/JP2023061448A/ja
Publication of JP2023061448A5 publication Critical patent/JP2023061448A5/ja
Priority to JP2026043076A priority patent/JP2026091873A/ja
Application granted granted Critical
Publication of JP7898267B2 publication Critical patent/JP7898267B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
JP2021171332A 2021-10-20 2021-10-20 小胞体ストレス抑制剤、神経変性疾患予防改善剤および認知症の予防・進行防止・改善剤、並びに食品 Active JP7898267B2 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2021171332A JP7898267B2 (ja) 2021-10-20 2021-10-20 小胞体ストレス抑制剤、神経変性疾患予防改善剤および認知症の予防・進行防止・改善剤、並びに食品
US18/702,472 US20240415797A1 (en) 2021-10-20 2022-10-19 Endoplasmic reticulum stress inhibitor, neurodegenerative disease preventing/improving agent, agent for prevention/progression prevention/improvement of dementia, and food product
PCT/JP2022/038842 WO2023068285A1 (ja) 2021-10-20 2022-10-19 小胞体ストレス抑制剤、神経変性疾患予防改善剤および認知症の予防・進行防止・改善剤、並びに食品
JP2026043076A JP2026091873A (ja) 2021-10-20 2026-03-17 小胞体ストレス抑制剤、神経変性疾患予防改善剤および認知症の予防・進行防止・改善剤、並びに食品

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2021171332A JP7898267B2 (ja) 2021-10-20 2021-10-20 小胞体ストレス抑制剤、神経変性疾患予防改善剤および認知症の予防・進行防止・改善剤、並びに食品

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026043076A Division JP2026091873A (ja) 2021-10-20 2026-03-17 小胞体ストレス抑制剤、神経変性疾患予防改善剤および認知症の予防・進行防止・改善剤、並びに食品

Publications (3)

Publication Number Publication Date
JP2023061448A JP2023061448A (ja) 2023-05-02
JP2023061448A5 JP2023061448A5 (cg-RX-API-DMAC10.html) 2024-10-28
JP7898267B2 true JP7898267B2 (ja) 2026-07-31

Family

ID=86059189

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021171332A Active JP7898267B2 (ja) 2021-10-20 2021-10-20 小胞体ストレス抑制剤、神経変性疾患予防改善剤および認知症の予防・進行防止・改善剤、並びに食品
JP2026043076A Pending JP2026091873A (ja) 2021-10-20 2026-03-17 小胞体ストレス抑制剤、神経変性疾患予防改善剤および認知症の予防・進行防止・改善剤、並びに食品

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026043076A Pending JP2026091873A (ja) 2021-10-20 2026-03-17 小胞体ストレス抑制剤、神経変性疾患予防改善剤および認知症の予防・進行防止・改善剤、並びに食品

Country Status (3)

Country Link
US (1) US20240415797A1 (cg-RX-API-DMAC10.html)
JP (2) JP7898267B2 (cg-RX-API-DMAC10.html)
WO (1) WO2023068285A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117298087A (zh) * 2023-10-17 2023-12-29 张岳峰 促血液药物颅内转运合剂及其应用
JP2025095964A (ja) * 2023-12-15 2025-06-26 リファインホールディングス株式会社 疲労回復剤、抗疲労作用剤および疲労回復用飲食物

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019052629A1 (en) 2017-09-12 2019-03-21 Sunregen Healthcare Ag LIPIDS HAVING AN IMPERATIVE NUMBER OF CARBON ATOMS AND THEIR USE AS A PHARMACEUTICAL COMPOSITION OR FOOD SUPPLEMENT
JP2019518034A (ja) 2016-06-08 2019-06-27 サンレーゲン ヘルスケア アーゲー 奇数個の炭素原子を有する脂質及び医薬組成物又は栄養補助食品としてのそれらの使用
WO2020054804A1 (ja) 2018-09-13 2020-03-19 リファインホールディングス株式会社 奇数脂肪酸エステルの製造方法及び培養組成物
JP2020533019A (ja) 2017-08-23 2020-11-19 シンプロミクス・リミテッド 制御可能なイントロンを用いる発現調節
WO2021020514A1 (ja) 2019-07-31 2021-02-04 リファインホールディングス株式会社 コラーゲン産生促進剤、シワ改善剤、皮膚外用剤および美容飲食品
WO2021107084A1 (ja) 2019-11-27 2021-06-03 リファインホールディングス株式会社 インスリン分泌促進剤並びにこれを用いた血糖値改善剤、糖尿病改善剤及び食品

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024075625A1 (ja) * 2022-10-02 2024-04-11 リファインホールディングス株式会社 視野欠損障害、光誘発眼組織障害およびその関連障害の予防剤、進行防止剤、改善剤、並びに食品

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019518034A (ja) 2016-06-08 2019-06-27 サンレーゲン ヘルスケア アーゲー 奇数個の炭素原子を有する脂質及び医薬組成物又は栄養補助食品としてのそれらの使用
JP2020533019A (ja) 2017-08-23 2020-11-19 シンプロミクス・リミテッド 制御可能なイントロンを用いる発現調節
WO2019052629A1 (en) 2017-09-12 2019-03-21 Sunregen Healthcare Ag LIPIDS HAVING AN IMPERATIVE NUMBER OF CARBON ATOMS AND THEIR USE AS A PHARMACEUTICAL COMPOSITION OR FOOD SUPPLEMENT
WO2020054804A1 (ja) 2018-09-13 2020-03-19 リファインホールディングス株式会社 奇数脂肪酸エステルの製造方法及び培養組成物
WO2021020514A1 (ja) 2019-07-31 2021-02-04 リファインホールディングス株式会社 コラーゲン産生促進剤、シワ改善剤、皮膚外用剤および美容飲食品
WO2021107084A1 (ja) 2019-11-27 2021-06-03 リファインホールディングス株式会社 インスリン分泌促進剤並びにこれを用いた血糖値改善剤、糖尿病改善剤及び食品

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Batrakov, S. G. et al.,Characterization of the molecular species of natural lipids by metastable ion mass spectra. I. Trigl,Bioorganicheskaya Khimiya,1978年,Vol.4,No.9,pp.1220-1231,ISSN 0132-3423
BOUREBABA, L. et al.,Cladophora glomerata methanolic extract decreases oxidative stress and improves viability and mitoch,Biomedicine & Pharmacotherapy,2019年,Vol.111,pp.6-18
Lipids,2011年,Vol.46,p.781-788, Table S5
MARYCZ, K. et al.,The Cladophora glomerata Enriched by Biosorption Process in Cr(III) Improves Viability, and Reduces,Mar. Drugs,2017年,Vol.15,385 (pp.1-18)
SASAKI, K. et al.,Microalgae Aurantiochytrium Sp. Increases Neurogenesis and Improves Spatial Learning and Memory in S,Frontiers in Cell and Developmental Biology,2021年02月,Vol. 8, Article 600575,pp.1-14
WANG, F. et al.,Antidiabetic Activity and Chemical Composition of Sanbai Melon Seed Oil,Evidence-Based Complementary and Alternative Medicine,2018年,Vol.2018, Article ID 5434156,pp.1-14
金本聡自、今泉和則,小胞体ストレスと疾患,生化学,Vol. 90,No. 1,p. 51-59

Also Published As

Publication number Publication date
US20240415797A1 (en) 2024-12-19
JP2023061448A (ja) 2023-05-02
WO2023068285A1 (ja) 2023-04-27
JP2026091873A (ja) 2026-06-04

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241018

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241018

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251118

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260317

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260623

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260721

R150 Certificate of patent or registration of utility model

Ref document number: 7898267

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150